Li Liu, MD
OncoLink Assistant Editor
Last Modified: October 23, 2000
Presenter: E. Paraskevaidis
Affiliation: Metaxas Cancer Hospital, Pireus, Greece
The majority of patients with brain metastases has a dismal survival of approximately 4 months. Various strategies have been investigated, including whole brain radiation therapy (WBRT), craniotomy, stereotactic radiosurgery boost, and chemotherapy, in an attempt to improve outcome. In this study, the researchers from France reported their Phase II randomized study of comparing WBRT with or without temozolomide (TMZ) in patients with brain metastases.
In this study, patients who received combined treatment with WBRT+ TMZ achieved more significant response rates in patients with brain metastases than the ones who had WBRT only. Concurrent administration of TMZ with WBRT appeared to enhance WBRT efficacy in patients with brain metastases. Survival and pattern of failure results are needed to further assess the efficacy of this treatment regimen.
Feb 10, 2011 - The results of two phase 3, randomized controlled trials suggest that two therapies, sunitinib and everolimus, hold promise in the treatment of patients with advanced pancreatic neuroendocrine tumors; the findings of these trials have been published in the Feb. 10 issue of the New England Journal of Medicine.
Nov 2, 2010